Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Missed Opportunities: 10 Questions We Wish Senators Had Asked At The Drug Pricing Hearing

Mar 07 2019

• By Jessica Merrill

Too Many Questions. Pile of colorful paper notes with question marks. Closeup. - Image

Related Content

Pfizer, Poised For A Tax Reform Windfall, Talks About Ways To Reinvest

Jan 30 2018

PhRMA’s Defensive Move On DTC Ads: Putting Drug List Prices ‘In Context’

Oct 16 2018

340B Provider Reforms Gaining Momentum In Congress

Jan 12 2018

Pfizer Decides Not To Challenge AbbVie's Humira Biosimilar Patents

Dec 01 2018

Big Pharma At The Senate: When It Comes To Yes Or No Questions, There Are Still A Few Maybes

Feb 28 2019

From Pricing To Patents: Hearing Signals A Potential New Focus

Feb 27 2019

Big Pharma Defuses Drug Pricing Landmines On Capitol Hill

Feb 26 2019

Merck Steps Out Of Insulin Glargine Market, But Says It Remains Committed To Biosimilars

Oct 11 2018

ICER’s ‘Unsupported Price Increase’ Report Due This Fall

Jan 18 2019

Industry's Drug Pricing Power Is Running On Fumes

Feb 07 2019

Pfizer Agrees To Roll Back Prices On 40 Drugs, Yielding To Pressure From Trump

Jul 11 2018

Who's Promised What: A Guide To Pharma Drug Pricing Pledges

Jul 23 2018

Pfizer Sets The Stage For A Biosimilar Showdown Over Exclusive Contracts

Sep 20 2017

Related Companies

Pfizer Inc.

Johnson & Johnson

Merck & Co., Inc.

Samsung Bioepis Co., Ltd.

AbbVie Inc.

Amgen, Inc.

Novartis AG

Roche Holding AG

Bristol Myers Squibb Company

Gilead Sciences, Inc.

GSK plc

Additional Topics

Pricing Debate Reimbursement Leadership

More from Pricing Debate

More from Market Access

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window